Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Ligand Pharmaceuticals (LGND) Income towards Parent Company: 2010-2025

Historic Income towards Parent Company for Ligand Pharmaceuticals (LGND) over the last 16 years, with Sep 2025 value amounting to $117.3 million.

  • Ligand Pharmaceuticals' Income towards Parent Company rose 1735.15% to $117.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $48.6 million, marking a year-over-year increase of 7.38%. This contributed to the annual value of -$4.0 million for FY2024, which is 142.16% down from last year.
  • Per Ligand Pharmaceuticals' latest filing, its Income towards Parent Company stood at $117.3 million for Q3 2025, which was up 2,319.50% from $4.8 million recorded in Q2 2025.
  • Ligand Pharmaceuticals' 5-year Income towards Parent Company high stood at $117.3 million for Q3 2025, and its period low was -$51.9 million during Q2 2024.
  • Over the past 3 years, Ligand Pharmaceuticals' median Income towards Parent Company value was -$1.7 million (recorded in 2023), while the average stood at $7.7 million.
  • Data for Ligand Pharmaceuticals' Income towards Parent Company shows a peak YoY increase of 5,273.51% (in 2024) and a maximum YoY decrease of 2,366.86% (in 2024) over the last 5 years.
  • Ligand Pharmaceuticals' Income towards Parent Company (Quarterly) stood at -$2.2 million in 2021, then slumped by 32.75% to -$3.0 million in 2022, then soared by 716.33% to $18.2 million in 2023, then tumbled by 270.93% to -$31.1 million in 2024, then soared by 1,735.15% to $117.3 million in 2025.
  • Its last three reported values are $117.3 million in Q3 2025, $4.8 million for Q2 2025, and -$42.5 million during Q1 2025.